Literature DB >> 6203963

Production and characterization of T cell clones specific for mouse hepatitis virus, strain JHM: in vivo and in vitro analysis.

J G Woodward, G Matsushima, J A Frelinger, S A Stohlman.   

Abstract

Mouse hepatitis virus, strain JHM, is a coronavirus capable of inducing both acute and chronic central nervous system disease. To characterize the cell-mediated immune response directed toward JHMV antigens, we have generated and analyzed the properties of four T cell clones reactive to JHMV antigens. All four clones are of the Ly-1+2- phenotype and show an antigen-specific, I-Ab-restricted proliferative response that is dependent on antigen-presenting cells (APC). The fine specificity of I-A restriction was revealed by their differential recognition of JHMV antigen in the context of mutant I-A molecules present on B6.C-H-2bm12 APC. Two clones were unable to recognize JHMV antigen presented on bm12 APC, whereas a third clone showed an equivalent response with both bm12 and wild type B6 APC. In the analysis of the viral specificity, three of the clones showed distinct cross-reactions with MHV-2 and very little if any cross-reaction with MHV-A59. In addition, three of three clones tested responded well to sucrose gradient-purified, UV-inactivated JHMV, indicating that their specificity is directed toward virus structural rather than nonstructural proteins. Finally, two of the clones were analyzed for their ability to induce a DTH reaction when injected together with antigen into the footpads of various mouse strains. Consistent with the in vitro data, both clones produced a marked DTH response only in those strains carrying the I-Ab genotype. These data demonstrate, both in vivo and in vitro, that at least one component of the cell-mediated immune response to JHMV is characterized by an Ly-1+2-, I-A-restricted T cell specific for JHMV structural proteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203963

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Skin test to assess virus-specific cytotoxic T-cell activity.

Authors:  T M Kündig; A Althage; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  T-cell-mediated clearance of mouse hepatitis virus strain JHM from the central nervous system.

Authors:  M A Sussman; R A Shubin; S Kyuwa; S A Stohlman
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  Antigen-specific T-cell lines transfer protective immunity against Trichinella spiralis in vivo.

Authors:  J Riedlinger; R K Grencis; D Wakelin
Journal:  Immunology       Date:  1986-05       Impact factor: 7.397

4.  T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts.

Authors:  Aaruni Khanolkar; Ross B Fulton; Lecia L Epping; Nhat-Long Pham; Dilea Tifrea; Steven M Varga; John T Harty
Journal:  J Immunol       Date:  2010-06-16       Impact factor: 5.422

5.  Studies on the mechanism of protection from acute viral encephalomyelitis by delayed-type hypersensitivity inducer T cell clones.

Authors:  S S Erlich; G K Matsushima; S A Stohlman
Journal:  J Neurol Sci       Date:  1989-04       Impact factor: 3.181

6.  Delayed-type hypersensitivity response in the central nervous system during JHM virus infection requires viral specificity for protection.

Authors:  S A Stohlman; M A Sussman; G K Matsushima; R A Shubin; S S Erlich
Journal:  J Neuroimmunol       Date:  1988-09       Impact factor: 3.478

7.  Immune response to a murine coronavirus: identification of a homing receptor-negative CD4+ T cell subset that responds to viral glycoproteins.

Authors:  J Mobley; G Evans; M O Dailey; S Perlman
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

8.  Relapsing encephalomyelitis following transfer of partial immunity to JHM virus.

Authors:  R A Shubin; M A Sussman; J O Fleming; S A Stohlman
Journal:  Microb Pathog       Date:  1990-05       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.